Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central anxious technique, conolidine modulates alternate molecular targets. A Science Advancements review identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://moseleyy319xaa9.blogcudinti.com/profile